Human diseases may be modeled in animals to allow preclinical assessment of putative
new clinical interventions. Recent, highly publicized failures of large clinical trials called into …

The last 10 years have seen a major shift in management of large vessel ischemic stroke
with changes towards ever-expanding use of reperfusion therapies (intravenous …

The Stroke Preclinical Assessment Network (SPAN) is a multicenter preclinical trial platform
using rodent models of transient focal cerebral ischemia to address translational failure in …

Stroke is the second leading cause of death and disability in the world. 1 In 1996, tissue
plasminogen activator (tPA) was approved by the US Food and Drug Administration and …

Use of rigorous study design methods and transparent reporting in publications are 2 key
strategies proposed to improve the reproducibility of preclinical research. Despite promotion …

Ischemic stroke is a highly morbid disease, with over 50% of large vessel stroke (middle
cerebral artery or internal carotid artery terminus occlusion) patients suffering disability …

Stroke, trauma, and neurodegenerative disorders cause loss of neurites (axons and
dendrites) in addition to neuronal death. Neurite loss may result directly from a primary …

Uric acid (UA) is a strong endogenous antioxidant that neutralizes the toxicity of peroxynitrite
and other reactive species on the neurovascular unit generated during and after acute brain …

Although dementia research has been dominated by Alzheimer's disease (AD), most
dementia in older people is now recognised to be due to mixed pathologies, usually …

Ischemic stroke causes acute CNS injury and long-term disability, with limited treatment
options such as surgical clot removal or clot-busting drugs. Neuroprotective therapies are …